Parexel Announces Updates to Board of Directors
Goldman Sachs’ Partner, Global co-Head of Private Equity Michael Bruun joins as new Director, succeeding current Goldman Sachs Board member...
Pharmaceutical
LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
PASADENA, CA, June 23, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE” or the “Company”) announced today...
scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes
BURLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing...
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
Presentations highlight preclinical and clinical advancements of bexotegrast program in primary sclerosing cholangitisSOUTH SAN FRANCISCO, Calif., June 23, 2023 (GLOBE...
SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia
NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a...
PaxMedica Comments on Common Stock Volatility
Engages ShareIntel to Track Market Activity TARRYTOWN, NY, June 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq:...
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein...
Sotera Health Finalizes Settlement of Ethylene Oxide Litigation in Illinois
99.7% of eligible claimants agree to participate in settlementCLEVELAND, June 22, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (“The Company”)...
Regeneration and Reinnervation of Spinal Cord in Rats Treated with NurExone’s Intranasal ExoPTEN
Figs. 1A-B Diffusion Tensor Imaging and MeasurementsTORONTO and TEL AVIV, Israel, June 22, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc....
Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII
DUBLIN, Ireland, June 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines...
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed...
Harvard Bioscience Set to Join Russell 2000® and 3000® Indexes
HOLLISTON, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced that it is...
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that Eboo...
Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management
Proceeds to Be Used to Redeem All of the Outstanding 5.75% Convertible Unsecured Senior Notes This news release constitutes a...
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
New Drug Application for arimoclomol in NPC to be filed as early as the third quarter of 2023¹EMERYVILLE, Calif., June 22,...
Avicanna Sponsors New Medical Cannabis Education and Training Campaign in Canada with the Canadian Consortium for the Investigation of Cannabinoids (“CCIC”)
Through a sponsorship agreement CCIC’s accredited Canadian Cannabis Syllabus will be made available to the medical community Avicanna Sponsors New...
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
ASLAN will receive up to $15 million in upfront and near-term payments and up to an additional $123.5 million based...
Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
This is the first-ever long-duration data reported for an anti-TL1A antibodyAt the expected Phase 3 once-monthly subcutaneous dose in the...
Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association
The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the safety and efficacy of AT-001 (caficrestat) in improving or...